Disclosures: Scott Friedman is a consultant to Galmed
Aramchol Downregulates SCD1 and Induces PPARg
in Hepatic Stellate Cells to Attenuate Cellular Activation and FibrogenesisBrittany Allen1, Jose M. Mato2, Amanda Craig1, David Fernandez-Ramos2, Fernando Lopitz-Otsoa2, Liat Hayardeny3, Augusto Villanueva1 and Scott L Friedman1,
1Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, NY 2CIC Biogune, Bilbao, Spain 3Galmed Pharmaceuticals, Tel Aviv, Israel
1. INTRODUCTION• Activation of hepatic stellate cells (HSCs) drives hepatic fibrosis
through a process that is inhibited by PPARg signaling.
• Aramchol (arachidyl amido cholanoic acid) is a fatty acid-bile acid
conjugate that reduces liver fat content in nonalcoholic fatty liver
disease (NAFLD) and improved nonalcoholic steatohepatitis (NASH)
without worsening fibrosis in a Phase 2b study (Abstract # LB-5).
• Aramchol attenuates fibrosis in two distinct models (MCD diet and
thioacetamide). In mice, Aramchol reduces liver fat by
downregulating the fatty acid synthetic enzyme stearoyl Co-A
desaturase 1 (SCD-1) in hepatocytes.
• The mechanism for Aramchol’s antifibrotic effect is not known;
moreover, although HSCs also store lipids as retinyl esters.
• The role of SCD-1 in HSCs and the impact of Aramchol on SCD-1
activity are unknown. .
3. METHODS• Serum-starved LX2 cells were treated with Aramchol (10 µM) for 24
or 48 hours. Fibrogenic gene expression and SCD-1 protein
expression were measured by qPCR and Western, respectively.
• RNAseq was performed at 24 and 48 h in duplicate. Differential gene
expression was assessed with DSeq2, while gene set enrichment
analysis (GSEA) and gene ontology (GO) analyses assessed
functionality of gene expression changes.
• Primary hepatocytes from C57BL/6 mice were harvested by
perfusion and treated with Aramchol (10 µM) for 48 hours in culture.
PPAR 𝛄 mRNA expression was measured by qPCR.
Figure 1: Aramchol downregulates SCD-1 mRNA and fibrogenic
genes, and upregulates PPAR𝛄 mRNA in HSCs. Based on RT-
PCR (N = 3) *p<0.05, **p<0.01, ***p<0.001.
2. AIM• To investigate the direct anti-fibrotic effect of Aramchol on HSCs
using LX-2, a human hepatic stellate cell line
• To define the mechanism of Aramchol’s effects on HSCs.
4. RESULTS
CONCLUSIONS• Aramchol elevates PPAR𝛄 mRNA and down regulates SCD-1 mRNA and protein and in hepatic stellate cells.
• By RNAseq and pathway analysis, Aramchol downregulates fibrogenic genes that are part of a clinically validated
HSC activation signature, including COL1A1 and ⍺SMA, as well as pathways involved in cholesterol biosynthesis &
homeostasis, and collagen formation.
• Aramchol upregulates PPAR𝛄 mRNA selectively in HSCs and not in hepatocytes.
Figure 5: Aramchol downregulates cholesterol
biosynthesis and collagen formation in HSCs. Gene Set
Enrichment Analysis of LX-2 cells after 24 (A) or 48 (B) hours
of treatment.
Funding support: Galmed Pharmeceuticals
Veh
icle
10 u
M
0.0
0.5
1.0
1.5
aSMA
Re
lativ
e G
en
e E
xp
res
sio
n
***
Veh
icle
10 u
M
0.0
0.5
1.0
1.5
COL1A1
Re
lativ
e G
en
e E
xp
res
sio
n
****
Veh
icle
10 u
M
0.0
0.5
1.0
1.5
b-PDGFR
Re
lativ
e G
en
e E
xp
res
sio
n
***
Veh
icle
10 u
M
0.0
0.5
1.0
1.5
MMP-2
Re
lativ
e G
en
e E
xp
res
sio
n
***
Veh
icle
10 u
M
0
2
4
6
8
10
PPARg
Re
lativ
e G
en
e E
xp
res
sio
n
***
Veh
icle
10 u
M
0.0
0.5
1.0
1.5
SCD1
Re
lativ
e G
en
e E
xp
res
sio
n
**
Veh
icle
10 u
M
0.0
0.5
1.0
1.5
aSMA
Re
lativ
e G
en
e E
xp
res
sio
n
***
Veh
icle
10 u
M
0.0
0.5
1.0
1.5
MMP-2
Re
lativ
e G
en
e E
xp
res
sio
n
*
Veh
icle
10 u
M
0.0
0.5
1.0
1.5
COL1A1
Re
lativ
e G
en
e E
xp
res
sio
n
Veh
icle
10 u
M
0
2
4
6
8
PPARg
Re
lativ
e G
en
e E
xp
res
sio
n
****
Veh
icle
10 u
M
0.0
0.5
1.0
1.5
b-PDGFR
Re
lativ
e G
en
e E
xp
res
sio
n
***
Veh
icle
10 u
M
0.0
0.5
1.0
1.5
SCD1
Re
lativ
e G
en
e E
xp
res
sio
n
BA
Figure 2: Aramchol downregulates SCD-1
in HSCs. Western Blot (A) and densitometry
(B) of downregulated SCD-1 protein in HSCs
treated with Aramchol for 24 or 48 hrs. (N=3)
*p<0.05, **p<0.01, ***p<0.001
Figure 3: RNASeq confirms downregulation of fibrogenic genes
and SCD-1 mRNA, and upregulation of PPAR𝛄 mRNA after 48 hrs
of treatment with Aramchol. The cholesterol efflux regulatory protein,
ABCA1, is also upregulated.
Figure 4: Aramchol does not
affect PPAR𝛄 mRNA expression
in primary mouse hepatocytes
after 48 hours of treatment. (N=3)
*p<0.05, **p<0.01, ***p<0.001
V V V 10 10 10 V V V 10 10 10
24hours 48hours
SCD-1
GAPDH
A B
Veh
icle
10 µ
M
0
50
100
150
24 Hours
Re
lati
ve P
rote
in E
xp
ress
ion
(% o
f v
eh
icle
co
ntr
ol)
*
Veh
icle
10 µ
M
0
50
100
150
48 Hours
Re
lati
ve
Pro
tein
Exp
ressio
n
(% o
f ve
hic
le c
on
tro
l)
*
A
B
Veh
icle
10 µ
M A
ram
chol
0.0
0.5
1.0
1.5
2.0
PPARg
Re
lativ
e G
en
e E
xp
res
sio
n